Omeros Corporation (NASDAQ: OMER) today announced that Gregory A.
Demopulos, M.D., chairman and chief executive officer, will present at
the UBS Global Healthcare Conference in New York next week. The
presentation is scheduled for Wednesday, May 22, 2019 at 8:00 a.m. EDT.
The presentation will be webcast. The live and archived webcasts can be
accessed on the investor relations page of company’s website at www.omeros.com.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, complement-mediated diseases, disorders of the central
nervous system and immune-related diseases, including cancers. The
company’s drug product OMIDRIA® (phenylephrine and ketorolac
intraocular solution) 1% / 0.3% is marketed for use during cataract
surgery or intraocular lens (IOL) replacement to maintain pupil size by
preventing intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. In the European Union, the European
Commission has approved OMIDRIA for use in cataract surgery and other
IOL replacement procedures to maintain mydriasis (pupil dilation),
prevent miosis, and to reduce postoperative eye pain.
Omeros has multiple Phase 3 and Phase 2 clinical-stage development
programs focused on complement-associated thrombotic microangiopathies,
complement-mediated glomerulonephropathies, cognitive impairment and
addictive and compulsive disorders. In addition, Omeros has a diverse
group of preclinical programs and a proprietary G protein-coupled
receptor (GPCR) platform through which it controls 54 new GPCR drug
targets and corresponding compounds, a number of which are in
preclinical development. The company also exclusively possesses a novel
antibody-generating platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005309/en/
Copyright Business Wire 2019